Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1125504

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the recommendations by the Joint Committee on Vaccination and Immunisation to reduce the infant pneumococcal vaccination schedule from three doses to two.
	tabling member printed	Baroness Masham of Ilton
	uin	HL15599
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom’s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.</p><p>The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI’s minutes which are attached.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL15600 question first answered 22/05/2019 14:50:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf title JCVI Minute 2015
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1125505

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what analyses they have conducted of the risks and benefits of reducing the infant pneumococcal vaccination schedule from 2+1 to 1+1; and whether they will publish the results any such analyses.
	tabling member printed	Baroness Masham of Ilton
	uin	HL15600
	answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom’s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.</p><p>The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI’s minutes which are attached.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL15599 question first answered 22/05/2019 14:50:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf title JCVI Minute 2015
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1127261

	registered interest
	date	16/05/2019
	answering body	Department for International Development
	answering dept id	20
	answering dept short name	International Development
	answering dept sort name	International Development
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to extend their engagement with the Advanced Market Commitment beyond the pilot for pneumococcal vaccine, run via Gavi, the Vaccine Alliance.
	tabling member printed	Lord Stevenson of Balmacara
	uin	HL15814
	answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>The Advance Market Commitment (AMC) for Pneumococcal Vaccines is a dynamic financing instrument of Gavi, the Vaccine Alliance. Its objective is to reduce deaths from severe pneumonia by reducing the cost of the pneumococcal vaccine. The AMC does this by incentivising vaccine manufacturers and generating greater competition by encouraging additional manufacturers to the market. So far, 114 million children have been vaccinated with AMC-supported pneumococcal vaccines, saving 762,000 lives.</p><p> </p><p>DFID has committed $485 million to AMC from 2010 until 2020. The AMC has consistently delivered and performs very strongly. It scored an A+ in its last Annual Review. The current end date is scheduled for December 2020. DFID are currently reviewing vaccine demand projections and in discussions with other stakeholders whether an extension is required in order to attract new manufacturers and generate wider benefits. This review is in line with our approach to maximise effectiveness and ensure good value for money.</p> answering member printed Baroness Sugg question first answered 30/05/2019 12:54:28 answering member 4584 label Biography information for Baroness Sugg
	tabling member	4175 label Biography information for Lord Stevenson of Balmacara

1127262

	registered interest
	date	16/05/2019
	answering body	Department for International Development
	answering dept id	20
	answering dept short name	International Development
	answering dept sort name	International Development
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what financial commitment they intend to make to the Advanced Market Commitment pilot for pneumococcal vaccine beyond 2020; and what estimate they have made of the expected total funding.
	tabling member printed	Lord Stevenson of Balmacara
	uin	HL15815
	answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>The Advance Market Commitment (AMC) for Pneumococcal Vaccines is a dynamic financing instrument of Gavi, the Vaccine Alliance. Its objective is to reduce deaths from severe pneumonia by reducing the cost of the pneumococcal vaccine. The AMC does this by incentivising vaccine manufacturers and generating greater competition by encouraging additional manufacturers to the market. So far, 114 million children have been vaccinated with AMC-supported pneumococcal vaccines, saving 762,000 lives.</p><p> </p><p>The expected total funding for DFID’s contribution to AMC is $485 million from 2010 until the programme completes in 2020. To date, the UK have made no new financial commitments for AMC beyond completion of the programme in 2020. As part of the planning process for the next phase for Gavi, the UK and other stakeholders are exploring all innovative financing options which can improve global immunisation in poor countries.</p> answering member printed Baroness Sugg question first answered 30/05/2019 12:54:48 answering member 4584 label Biography information for Baroness Sugg
	tabling member	4175 label Biography information for Lord Stevenson of Balmacara

1127263

	registered interest
	date	16/05/2019
	answering body	Department for International Development
	answering dept id	20
	answering dept short name	International Development
	answering dept sort name	International Development
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the effectiveness of the Advanced Market Commitment for pneumococcal vaccines; and whether it should be continued.
	tabling member printed	Lord Stevenson of Balmacara
	uin	HL15816
	answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>The Advance Market Commitment (AMC) for Pneumococcal Vaccines (PCV) incentivises vaccine manufacturers and generates competition by encouraging additional manufacturers to the market. So far, 114 million children have been vaccinated with AMC-supported pneumococcal vaccines, saving 762,000 lives.</p><p> </p><p>The UK assess AMC to be an effective and efficient mechanism to improve vaccine coverage at a lower cost. It scored an A+ in its last annual review. In March 2019, Pfizer reduced the price of PCV for 73 developing countries from US$3.30 in 2017 to US$2.90 per dose. This further reduction is estimated to save Gavi and developing country governments up to US$ 4.1 million.</p><p> </p><p>An independent 2015 evaluation identified AMC’s supply arrangements as a critical factor in encouraging vaccine manufacturers to expand their capacity to produce safe, effective vaccines. As part of the planning process for the next phase for Gavi, the UK and other stakeholders are exploring all innovative financing options which can improve global immunisation in poor countries.</p> answering member printed Baroness Sugg question first answered 30/05/2019 12:55:11 answering member 4584 label Biography information for Baroness Sugg
	tabling member	4175 label Biography information for Lord Stevenson of Balmacara

1130248

	registered interest
	date	05/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answers by Baroness Blackwood of North Oxford on 22 May (HL15599 and HL15600), what plans they have to carry out a formal public consultation before implementing a 1+1 vaccine schedule in the UK.
	tabling member printed	Baroness Masham of Ilton
	uin	HL16109
	answer	answer is ministerial correction date of answer 18/06/2019 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom immunisation programme. It bases its recommendations on review of a wide range of scientific and other evidence, including from the published literature, and commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness. It can consult with stakeholders on its advice when it deems this necessary.</p><p>Between January and April 2018, the JCVI undertook a focused stakeholder consultation on its proposed advice about a change to the UK’s childhood pneumococcal conjugate vaccine schedule. The JCVI is well placed to carry out stakeholder consultation to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme, including identifying who to target to obtain the evidence it needs to inform its advice. It is the JCVI rather than the Government that is best placed to carry out consultation about scheduling within the vaccine programme and who to target the consultation at.</p> answering member printed Baroness Blackwood of North Oxford question first answered 18/06/2019 12:51:32 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1130615

	registered interest
	date	06/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answers by Baroness Blackwood of North Oxford on 22 May (HL15599 and HL15600), whether they will place a copy of the Public Health England modelling on the estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales, presented at the 37th annual meeting of the European Society for Paediatric Infectious Diseases, in the Library of the House.
	tabling member printed	Baroness Masham of Ilton
	uin	HL16159
	answer	answer is ministerial correction date of answer 18/06/2019 answer text <p>The modelling by Public Health England (PHE) on the estimated impact of revising the pneumococcal conjugate vaccine schedule from 2+1 to 1+1 has been accepted for publication by Public Library of Science (PLoS) Medicine and is due to be published shortly. Release of the modelling data prior to its publication could prejudice publication.</p><p>The poster<em> Estimated impact of revising the 13-valent pneumococal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: a modelling study,</em> presented by PHE at the European Society for Paediatric Infectious Diseases, provides context for the model on additional invasive pneumococcal disease cases, pneumococcal community acquired pneumonia cases and deaths. A copy of the poster is attached.</p><p>More detail will be available once the published paper is available.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16160 question first answered 18/06/2019 12:28:36 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name PHE_poster.pdf title PHE_poster
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1130616

	registered interest
	date	06/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answers by Baroness Blackwood of North Oxford on 22 May (HL15599 and HL15600) and the Public Health England modelling on the estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales, presented at the 37th annual meeting of the European Society for Paediatric Infectious Diseases, how many additional (1) invasive pneumococcal disease cases, (2) pneumococcal community acquired pneumonia cases, and (3) deaths, they predict as a result of a change to a 1+1 vaccine schedule over the next five years.
	tabling member printed	Baroness Masham of Ilton
	uin	HL16160
	answer	answer is ministerial correction date of answer 18/06/2019 answer text <p>The modelling by Public Health England (PHE) on the estimated impact of revising the pneumococcal conjugate vaccine schedule from 2+1 to 1+1 has been accepted for publication by Public Library of Science (PLoS) Medicine and is due to be published shortly. Release of the modelling data prior to its publication could prejudice publication.</p><p>The poster<em> Estimated impact of revising the 13-valent pneumococal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: a modelling study,</em> presented by PHE at the European Society for Paediatric Infectious Diseases, provides context for the model on additional invasive pneumococcal disease cases, pneumococcal community acquired pneumonia cases and deaths. A copy of the poster is attached.</p><p>More detail will be available once the published paper is available.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16159 question first answered 18/06/2019 12:28:37 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name PHE_poster.pdf title PHE_poster
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1177078

	registered interest
	date	07/02/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure that the pneumococcal vaccine is available to all people who are eligible.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	13990
	answer	answer is ministerial correction date of answer 12/02/2020 answer text <p>The Department is aware that there is currently limited availability of the pneumococcal polysaccharide vaccine (PPV23), due to manufacturing capacity constraints. Further deliveries of the vaccines are due at the end of February 2020.</p><p>Public Health England has issued comprehensive guidance to the National Health Service that provides information to clinicians on the management of potentially affected patients during this time of limited availability. General practices have been advised to prioritise PPV23 vaccinations based on clinical risk and to plan vaccinations to ensure demand is more consistent across the year.</p><p>On the 6 November 2019, PPV23 was added to the list of medicines that cannot be parallel exported, further protecting United Kingdom supplies and vaccine availability.</p><p>The vaccine differs from the pneumococcal conjugate vaccine (PCV13) vaccine used for the routine childhood programme. There is no supply issue affecting the PCV13 vaccine used in infants and toddlers—but this vaccine is not suitable for protection of older people.</p><p> </p><p> </p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 12/02/2020 17:27:14 answering member 4380 label Biography information for Jo Churchill
	tabling member	4249 label Biography information for Anne Marie Morris

1184423

	registered interest
	date	11/03/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that pharmacies have adequate supplies of the PPV23 vaccine.
	tabling member constituency	Streatham
	tabling member printed	Bell Ribeiro-Addy
	uin	28075
	answer	answer is ministerial correction date of answer 19/03/2020 answer text <p>The Department is aware that there is currently limited availability of the pneumococcal polysaccharide vaccine (PPV23). There have been intermittent supply issues over the last 2-3 years due to manufacturing capacity constraints and an increase in global demand for the vaccine.</p><p>Public Health England has issued comprehensive guidance to the National Health Service clinicians on the management of potentially affected patients during this time of limited availability. General Practices have been advised to prioritise PPV23 vaccinations based on clinical risk and to plan vaccinations to ensure demand is more consistent across the year.</p><p>On 6 November 2019, PPV23 was added to the list of medicines that cannot be parallel exported, further protecting United Kingdom supplies and vaccine availability.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 19/03/2020 12:24:02 answering member 4380 label Biography information for Jo Churchill
	tabling member	4764 label Biography information for Bell Ribeiro-Addy